Navigation Links
Humira in Medical News

Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohn's Disease

Humira Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 26, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceuti...

Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies

Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance Charges and Other Protocols on Remicade and Humira, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research ...

Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium

... tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-availa...

U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic

...ary Advantages in Immune Biologics: Tightening Payer Control Offers Opportunities for Differentiation , Centocor Ortho Biotech's Remicade and Abbott's humira stand to most directly benefit from this strategy as these drugs are currently marketed and/or in development for multiple indications. Howeve...

Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA

...errupting a protein that causes inflammation and damage to bones, cartilage and other tissue. They include Remicade (infliximab), Enbrel (etanercept), humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab). "FDA announced that it has completed its analysis of TNF blockers and has concl...

Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013

...eaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's humira and Schering-Plough's Remicade which recorded sales of $50 million and $43 ...in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer humira and Remicade, respectively. "Competition among TNF-alpha inhibito...

Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit

...trol Offers Opportunities for Differentiation , the majority of surveyed pharmacy directors say they currently cover Amgen/Wyeth's Enbrel and Abbott's humira solely as a pharmacy benefit, but cover other immune biologics as a medical benefit. The report finds that payers expect the shift of biolog...

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

...orable 12.4 percent effect of exchange rates. U.S. humira sales were $635 million, up 20.9 percent. W...e Reported Pharmaceutical Products humira $635 20.9 $676 44.0 (2...ange Reported Pharmaceutical Products humira $1,311 32.8 (12....

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...e world's largest drug market, the US, is due primarily to the inclusion of humira and Enbrel into Medicare Part D reimbursement in early 2006. New products t...ay treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, humira and Remicade. New products in the market, such as Rituxan and Orencia made ...

Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)

...he majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, humira and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self ...
Humira in Medical Technology

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA Patients Reported Job Loss When Treated With HUMIRA Combination Therapy Compared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) is one of the most common causes of disability in the Weste...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... Additional Analysis Shows humira Effectively Treats Adult Patients with Moderate t...ks, patients who had achieved adequate response to humira (as measured by PASI 75, or greater than 75 percen...ed into two groups. One group continued to receive humira and the other was given placebo. Beginning at week...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

... Three of Four humira Patients from CHARM Study in Remission at One Year...study author. "In this study, many patients taking humira during a lengthened treatment period showed clinic...ongoing extension study focused on the efficacy of humira in maintaining remission and achieving response du...

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... Fifth Disease Indication for humira Provides Patients with Visible Clearance of Infl...systemic therapies are medically less appropriate. humira should only be administered to patients who will b... or better at week 16 of treatment versus placebo. humira has 10 years of clinical trial experience beginnin...

Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award

...he m2000 and HIV-1 viral load test, PathVysion and humira are just a few examples of the caliber of research...iated with congenital disorders and cancer. About humira In the United States, humira is approved by the Food and Drug Administration (F...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

... humira Data Showed 57 Percent Reduction in Risk of Hospit...ted to assess the effect of ongoing treatment with humira on the risk of hospitalization. At one year, this ...ent) were more than twice as likely as patients on humira (5.9 percent; p<0.01) to be hospitalized from Croh...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

... - Co-Injection of rHuPH20 with humira Estimated to Increase the Maximal Steady State Sub...ging from 1,600 U to 12,800 U) and a fixed dose of humira (40 mg) injected every two weeks. Patients with rh...ctions were compared with regard to PK and safety. humira is a registered trademark of Abbott Laboratories. ...
Humira in Biological News

Researchers create mouse lacking key inflammation gene

...own and studied NF-kB transcriptional regulator. Drugs regulating TNF-alpha through the better-known NF-kB pathway such as Remicade, Embrel, and humira represent a multibillion market. The LITAF transcription factor offers a new approach to treating inflammatory disorders along with other immunologic...
Humira in Biological Technology

Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists

EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends (R) : Psoriasis , the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in th...

Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline

...dministration (FDA) approval in the first quarter. Abbott also received approval from the Japanese Ministry of Health, Labour and Welfare for humira for the treatment of rheumatoid arthritis in patients with inadequate response to conventional therapy. -- SIMCOR(R), a fixed-dose combinatio...

Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011

...b has advantages over sales-leading Enbrel on this attribute. "Clinical data and thought leader opinion indicate that ustekinumab and Abbott/Eisai's humira outperform Enbrel on efficacy and delivery measures," said Irene Koulinska, analyst at Decision Resources. "But the major improvement in efficacy offe...

Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis

...nd almost 20 percent achieving complete clearance, humira shows tremendous promise for physicians and people... decision granting the marketing authorization for humira as a treatment for psoriasis in the European Union...s indication. "The skin clearance we have seen in humira psoriasis clinical trials, combined with ten years...

First half of 2006 roundup: Big Pharma trumps biotech

...n to acquire new products that will generate in excess of $1 billion each. The case of Abbott Labs' stock price is a little strange as its new drug humira continues to grow beyond original expectations and has achieved additional FDA labeling approval. Furthermore, Abbott's move to aid Boston Scientific ...
Other Tags
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of ... cross-country walk to raise awareness and money for the Pulmonary Hypertension Association (PHA). ... at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning ...
(Date:7/2/2015)... (PRWEB) , ... July 02, ... ... wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on the ... development. Complete report on negative pressure wound therapy (NPWT) with 22 market ...
(Date:7/2/2015)... ... ... Time Pain Relief (RTPR), makers of the popular rub-on pain relief lotion and products, ... The Fifth Annual Big Sky Professional Bull Riders Event being held this month at Big ... relief lotion and products at the family friendly event that features two days of bull ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from ... in Anniston for specialized disaster training. The team – composed of four clinicians ... California Hospital Association who attended the training, which is dedicated to preparing first ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. ... has been retained to lead a national chief operating officer recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
Breaking Medicine News(10 mins):Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 2Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 3Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
(Date:6/9/2015)... , June 09, 2015 Research and ... of the "Gesture Recognition & Touchless Sensing ... Electronics, Automotive, & Others), Product (Biometric & Sanitary ... 2020" report to their offering. ... is expected to reach $ 23.55 Billion by ...
(Date:6/8/2015)...  The Secure Identity & Biometrics Association ... Troy Potter of L-3 National Security Solutions ... non-profit association that was established in February 2014 ... of solutions that protect and secure identity across ... Photo - ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
Other Contents